Cell cycle and proliferation markers in neuroepithelial tumors

Anticancer Research

Volumn 17, Issue 6 B, 1997, Pages 4135-4143

  Cavalla, Paola ^a   Schiffer, Davide ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Brain tumors; Cell cycle; Proliferation

Indexed keywords

BROXURIDINE; CELL MARKER; CYCLINE; KI 67 ANTIGEN; THYMIDINE;

ANAPLASTIC CARCINOMA; BRAIN TUMOR; CANCER DIAGNOSIS; CELL CYCLE; CELL LABELING; CELL PROLIFERATION; CHROMOSOME NOR; CYTOMETRY; HUMAN; HUMAN CELL; LABELING INDEX; MITOSIS; NEUROEPITHELIOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TECHNIQUE;

BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASES; GLIOBLASTOMA; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGODENDROGLIOMA; PROGNOSIS; TRANS-ACTIVATION (GENETICS);

EID: 0031460766     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Hoshino T: Cell kinetics of brain tumors. In: Neurobiology of Brain Tumors. Voi 4. Eds. M Salcman. Baltimore: Williams and Wilkins 145-159, 1991.
2. Graha X, Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CKIs). Oncogene 11: 211-219, 1995.
3. Matsushime H, Quelle DE, Shurtleff SA, Shibuiya M, Sherr CJ, Kato JY: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14: 2066-2076, 1994.
4. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ: Colony-stymulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65: 701-713, 1991.
5. Ajchenbaum F, Ando K, DeCaprio JA, Griffin JD: Independent regulation of human Dtype cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem 268: 4113-4119, 1993.
6. Morgan DO. Principles of CDK regulation. Nature 374: 131-134, 1995.
7. Nevins RN: E2F: A link between the Rb Tumor Suppressor Protein and viral oncoproteins. Science 258: 424-429, 1992.
8. Cavanaugh AH, Hempel WM, Taylor W, Rogalsky V, Todorov G, Rothblum LI: Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 374: 177-180, 1995.
9. Nasmyth K: Retinoblastoma protein: Another role rolls in. Nature 382: 28-29, 1996.
10. Harper JW, Adami GR; Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin dependent kinases. Cell 75: 805-816, 1993.
11. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific infibition of cyclin D/CDKA. Nature 366: 704-707, 1993.
12. Louis DN: A molecular genetic model of astrocytoma histopathology. Bran Pathol 7: 755-764, 1997.
13. Rey JA, Beilo MJ, Jimenez-Lara AM, Vaquera J, Kusak ME, De Campos JM, Sarasa JL, Pestana A: Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer 51: 703-706, 1992.
14. Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11-21, 1994.
15. Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a tumor suppressor DNA complex: understanding tumorigenic mutations. Science 265: 346-355, 1994.
16. Leonardo AD, Linke SP, Clarkin K, Wahl GM: DNA damage triggers a prolonged p53 dependent G1 arrest and long term induction of Cip 1 in normal human fibroblasts. Genes and Development 8: 2540-2551, 1994.
17. Stewart N, Hicks GG, Paraskevas F, Mowat M: Evidence for a second cell cycle block at G2/M by p53. Oncogene 10: 109-115, 1995.
18. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 343-347, 1991.
19. Hermanson N, Funa K, Hartman M, Claesson-Welsch L, Helding CH, Westermark B, Nister M: Platelet-derived growth factor and its receptor in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219, 1992.
20. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W: Increased levels of p21 WAF1/Cip1 in human brain tumors. Oncogene 11: 2021-2028, 1995.
21. Sidransky D, Mikkelsen T, Schwechheimer K, Rosemblum M, Cavenee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355: 846-847, 1992.
22. Jong WH, Chou D, Ueki K, Harsh GR, von Deimling A, Gusella JF, Mohrenweiser HW, Louis DN: Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 54: 622-626, 1995.
23. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M: Homozigous deletion of the multiple tumor suppressor gene 1 in the progression of astrocytomas. Cancer Res 55: 20-23, 1995.
24. INK4 Or retinoblastoma protein (pRb) or amplification-associated overexpression of CDK4 is observed in distint subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833-4836, 1995.
25. Schimdt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletions or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994
26. Rollbroker B, Waha A, Louis DN, Wiestler OD, von Deimling A: Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme, Acta Neuropathol 92: 70-74, 1996.
27. Hall PA, Coates PJ: Assessment of cell proliferation in pathology-what next? Histopathology 26: 105-112, 1995.
28. Quinn CM, Wright NA: The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 160: 93-102, 1990.
29. Hall PA, Levison DA: Review: Assessment of cell proliferation in histological material. J Clin Pathol 43: 184-192, 1990.
30. Coons SW: Proliferation markers in the evaluation of gliomas. Special Course A.A.N.P. Vancouver, June 12, 1996.
31. Schiffer D, Chió A, Giordana MT, Leone M, Soffietti R: Prognostic value of histologic factors in adult cerebral astrocytoma. Cancer 61: 1386-1393, 1988.
32. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW: Grading of oligodendrogliomas. Cancer 52: 2107-2114, 1983.
33. Mork SJ, Halvorsen TBH, Lindegaard KF, Eide GE: Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 45: 65-78, 1986.
34. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC, Bullard DE: Clinicopathologic correlations in the Oligodendroglioma. Cancer 59: 1345-1352, 1987.
35. Kros JM, van Eden CG, Vissers CJ, Mulder AH, van der Kwast TH: Prognostic relevance of DNA flow cytometry in Oligodendroglioma. Cancer 69: 1791-1798, 1992.
36. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas. A simple and reproducible method. Cancer 62: 2152-2165, 1988.
37. Hoshino T and Wilson CB: Cell kinetics analysis of human malignant tumors (gliomas). Cancer 44: 956-962, 1979.
38. Broggi G, Franzini A, Costa A, Melcarne A, Allegranza A: Cell Kinetics o neuroepithelial tumors in serial stereotactic biopsies, a new combined approach. Appl Neurophysiol 48: 472-476, 1985.
39. Hoshino T, Townsend J, Muraoka I, Wilson C: An autoradiographic study of human gliomas: Growth kinetics of anaplastic astrocytoma and glioblastoma multiforme. Brain 103: 967-984, 1980.
40. Morimura T, Kitz K, Budka H: In situ analysis of cell kinetics in human brain tumors. Acta Neuropathol 77: 276-82, 1989.
41. Hoshino T, Nagashima T, Murovic JA, el al: Cell kinetic studies of in situ brain tumors with bromodeoxyuridine. Cytometry 6: 627-632, 1985.
42. Hoshino T, Nagashima T, Murovic JA. et al: In situ cell kinetic studies on human neuroectodermal tumors using bromodeoxyuridine. J Neurosurg 64: 453-459, 1986a.
43. Hoshino T, Rodriguez LA, Cho KG, et al: Prognostic implications of the proliferative potential of low grade astrocytomas. J Neurosurg 69: 839-842, 1988b
44. Ito S, Chandler K, Prados M, Lamborn K, Wynne J, Malec M, Wilson C, Davis R, Hoshino T: Proliferative potential and prognostic evaluation of low-grade astrocytomas. Ncuro-Oncol 19: 1-9, 1994.
45. Hoshino T, Nagashima T, Murovic JA, et al: Proliferative potential of human meningiomas of brain. A cell kinetic study with bromodeoxyuridine. Cancer 58: 1466-1472, 1986b.
46. Ritter A, Sawaya R, Hess K, Levin V, Bruner J: prognostic significance of bromodeoxiuridine labeling in primary and recurrent glioblastoma multiforme. Neurosurgery 35: 192, 1994.
47. Wacker M, Hoshino T, Ahn D, Davis R, Prados M: The prognostic implications of histologic classification and bromodeoxyuridine labeling index of mixed gliomas. J NeuroOncol 19: 113-122, 1994.
48. Schiffer D, Giordana MT, Vigliani MC, Cavalla P: Relationship between glial reaction to a stab wound and tumor development after transplacental ENU in the rat. Acta Neuropathol 83: 30-38; 1991.
49. Burger PC, Shibata T, Kleihues P: The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 10: 611-617, 1986.
50. Ostertag CB, Volk B, Shibata T, Burger P, Kleihues P: The monoclonal antibody Ki-67 as a marker for proliferative cells in stereotactic biopsies of brain tumors. Acta Neurochir 89: 117-121, 1987.
51. Decken M, Reifenberger G, Wechsler W: Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 115: 179-188, 1989.
52. Raghavan R, Steart PV, Weller RO: Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathol and Appl Neurobiol 16: 123-133, 1990.
53. Schroder R, Bien K, Kott R, Meyers I, Vossing R: The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol 82: 389-94, 1991.
54. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol 81: 675-9, 1991.
55. Jaros E, Perry RH, Adam L, et al: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66: 373-85, 1992.
56. Coons SW, Johnson PC: Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 52: 609-18, 1993 a.
57. Cattoretti G, Becker MHG, Key J, et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwaveprocessed formalin-fixed paraffin sections. J Pathol 168: 357-363, 1992
58. Onda K, Davis RL, Wilson CB, Hoshino T: Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme. Acta Neuropathol 87: 586-93, 1994.
59. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T: Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol 87: 47-54, 1994.
60. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helin HJ: Prognostication of astrocytoma patient survival by Ki67 (MIB 1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275-282, 1994.
61. Hoyt JH, Gown AM, Kim DK, Berger MS: Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neuro-Oncol 24: 163-169, 1995.
62. Davis RL, Onda K, Shubuka M, Lamborn K, Hoshino T: Proliferation markers in gliomas: a comparison of BUdR, Ki-67, and MIB-1. J Neuro-Oncol 24: 9-12, 1995.
63. Coons SW, Johnson PC: MlB 1/Ki-67 labeling index predicts patient survival for oligodendroglial tumors. J Neuropathol Exp Neurol 54: 440, 1995 (abs).
64. Schiffer D, Cavalla P, Chio A, Richiardi P, Giordana MT: Proliferative activity and prognosis of low-grade Astrocytotnas. J Neuro-Oncol, in press, 1997.
65. Schiffer D, Cavalla P, Chió A, Richiardi P, Giordana MT: Proliferative activity and prognosis of low-grade astrocytomas. J Neuro-Oncol, in press, 1997.
66. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H: Cyclin/PCNA is the auxiliary protein of DNA polimerase delta. Nature 326: 515-520, 1987.
67. Coltrera MD, Gown AM: PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines. J Histochem Cytochem 39: 23-30, 1991.
68. Kreipe H, Zeidler R, Fischer L, Feist H: Immunocytochemical assessment of cell proliferation. In: Cell proliferation assessment in oncology, Hofstadter F, Kunchel R, Rushoff J. Virchow Arch 427: 324-326, 1995.
69. Shivij MKK, Kenny MK, Wood HD: Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69: 367-374, 1992.
70. Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, Barnes DM, Gillet CE, Camplejohn R, Dover R, Waseen NH, Lane DP: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294, 1990.
71. Allegranza A, Girlando S, Arrigoni GL, et al: Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchow Arch (A) 419: 417-423, 1991.
72. Revesz T, Alsanjari N, Darling JL, et al: Proliferating cell nuclear antigen (PCNA): expression in samples of human astrocytic gliomas. Neuropathol and Appl Neurobiol 19: 152-158, 1993.
73. Karamitopoulou E, Perentes E, Melachrinou M, Maraziotis T: Proliferating cell nucler antigen immunoreactivity in human central nervous system neoplasms. Acta Neuropathol 85: 316-22, 1993
74. Schiffer D, Chio A, Giordana MT, Pezulo T, Vigliani MC: Proliferating cell nuclear antigen expression in brain tumors and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathol 95: 495-502, 1993.
75. Khoshyomm S, Maier H, Morimura T, Kitz K, Budka H: Immunostaining for proliferating cell nuclear antigen;: its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol 86: 582-589, 1993.
76. Celis JE, Celis A: Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 82: 3262-6, 1985.
77. Linden MD, Torres FX, Kubus J, Zarbo RJ: Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol 97: S4-S12, 1992..
78. Vigliani MC, Chio A, Pezzulo T et al: Proliferating cell nuclear antigen (PCNA) in lowgrade astrocytomas: its prognostic significance. Tumori 80: 295-300, 1994.
79. Schiffer D, Dutto A, Cavalla P, Chio A, Bosone I, Villani R, Bellotti C: Prognostic factors in oligodendrogliomas: importance of MIB-1. Can J Neurol Sci. in press, 1997.
80. Coons S, Johnson P, Pearl D: Prognostic significance of flow-cytometry deoxyribonucleic acid analysis of human astrocytomas. Neurosurgery 35: 119-126, 1994.
81. Salmon I, Kiss R: Relationship between proliferative activity and ploidy level in a series of 530 human brain tumors, including astrocytomas, meningiomas, schwannomas, and metastases. Hum Pathol 24: 329-335, 1993
82. Coons SW, Johnson PC: Regional heterogeneity in the DNA content of human gliomas. Cancer 72: 3052-3060, 1993 b.
83. Steel GG: Growth kinetics of tumors. Cell population kinetics in relation to the growth of and the treatment of cancer. Oxford, University Press, 1977.
84. Arends MJ, McGregor AH, Willie AH: Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J of Pathol 144: 1045-57, 1994.
85. Migheli A, Cavalla P, Marino S, Schiffer D: A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 53: 606-616, 1994.
86. Schiffer D, Cavalla P, Chib A, Giordana MT, Marino S, Mauro A, Migheli A: Tumor cell proliferation and apoptosis in medulloblastoma. Acta Neuropathol 87: 362-370, 1994.
87. Schiffer D, Cavalla P, Migheli A, Chio A, Giordana MT: Apoptosis and cell proliferation in neuroepithelial tumors. Neurosci Lett 195: 81 -84, 1995.
88. Ellison DW, Steart PV, Gatter KC, Weller RO: Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bc1-2 and p53 proteins. Neuropathology and Applied Neurobiology 21: 352-361, 1995.
89. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Research 55: 5528-5530, 1995
90. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer S: Bcl-2 is an inner mitochondria! membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
91. White E: Life, death, and the pursuit of apoptosis. Genes and Devel 10: 1-15, 1996
92. Alderson LM, Castleberg RL, Harsh GL, Louis DN, Henson JW: Human gliomas with wild-type p43 express bcl-2. Cancer Res 55: 999-1001, 1995.
93. Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L: Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neuro-Oncology 27: 101-109, 1996
94. Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J: Bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 88: 520-526, 1994.